UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

———————

FORM 10-Q

þ	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended MARCH 31, 2020
OR
¨	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from __________  to __________

Commission file number: 0-14942

PRO-DEX, INC.

(Exact name of registrant as specified in its charter)

———————

COLORADO	84-1261240
(State or other jurisdiction of	(I.R.S. Employer
incorporation or organization)	Identification No.)

2361 McGaw Avenue, Irvine, California 92614

(Address of principal executive offices and zip code)

(949) 769-3200

(Registrant's telephone number, including area code)

———————

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, no par value	PDEX	NASDAQ Capital Market

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þ  No ¨

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes þ  No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer   ¨	Accelerated filer   ¨
Non-accelerated filer     þ	Smaller reporting company  þ
	Emerging growth company  ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨  No þ

Indicate the number of shares outstanding of each of the registrant’s classes of common stock outstanding as of the latest practicable date: 3,811,137 shares of common stock, no par value, as of May 5, 2020.

PRO-DEX, INC.

QUARTERLY REPORT ON FORM 10-Q

FOR THE THREE AND NINE MONTHS ENDED MARCH 31, 2020

TABLE OF CONTENTS

	Page
PART I — FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS (Unaudited)	1
Condensed Balance Sheets as of March 31, 2020 and June 30, 2019	1
Condensed Statements of Operations and Comprehensive Income (Loss) for the Three and Nine Months Ended March 31, 2020 and 2019	2
Condensed Statements of Shareholders’ Equity for the Three and Nine Months Ended March 31, 2020 and 2019	3
Condensed Statements of Cash Flows for the Nine Months Ended March 31, 2020 and 2019	4
Notes to Condensed Financial Statements	6
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	15
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK	22
ITEM 4. CONTROLS AND PROCEDURES	22
PART II — OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS	24
ITEM 1A. RISK FACTORS	24
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS	25
ITEM 5. OTHER INFORMATION	25
ITEM 6. EXHIBITS	25
SIGNATURES	26

PART I — FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

PRO-DEX, INC.

CONDENSED BALANCE SHEETS

(Unaudited)

(In thousands, except share amounts)

	March 31, 2020			June 30, 2019
ASSETS
Current Assets:
Cash and cash equivalents	$	4,378		$	7,742
Investments		2,771			2,649
Accounts receivable, net of allowance for doubtful accounts of $6 and $0 at March 31, 2020 and at June 30, 2019, respectively		4,170			4,100
Deferred costs		391			430
Inventory		8,643			6,239
Prepaid expenses and other current assets		225			623
Total current assets		20,578			21,783
Equipment and leasehold improvements, net		2,732			2,726
Right of use asset, net		3,026			—
Intangibles, net		138			129
Deferred income taxes, net		53			260
Investments		1,659			582
Other assets		42			40
Total assets	$	28,228		$	25,520
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current Liabilities:
Accounts payable	$	1,912		$	1,996
Accrued expenses		1,524			1,437
Deferred revenue		360			215
Note payable and capital lease obligations		642			622
Total current liabilities		4,438			4,270
Deferred rent		—			146
Lease liability, net of current portion		2,857			—
Income taxes payable		325			162
Notes and capital leases payable, net of current portion		3,449			3,934
Total non-current liabilities		6,631			4,242
Total liabilities		11,069			8,512
Shareholders’ equity:
Common shares; no par value; 50,000,000 shares authorized; 3,837,490 and 4,039,491 shares issued and outstanding at March 31, 2020 and June 30, 2019, respectively		12,970			15,815
Accumulated other comprehensive loss		(1,162	)		(549	)
Retained earnings		5,351			1,742
Total shareholders’ equity		17,159			17,008
Total liabilities and shareholders’ equity	$	28,228		$	25,520

The accompanying notes are an integral part of these condensed financial statements.

1

PRO-DEX, INC.

CONDENSED STATEMENTS OF OPERATIONS
AND COMPREHENSIVE INCOME (LOSS)

(Unaudited)

(In thousands, except per share amounts)

	Three Months Ended March 31,						Nine Months Ended March 31,
	2020			2019			2020			2019
Net sales	$	8,508		$	6,854		$	23,710		$	20,168
Cost of sales		5,298			4,591			14,855			12,930
Gross profit		3,210			2,263			8,855			7,238
Operating (income) expenses:
Selling expenses		161			122			438			252
General and administrative expenses		725			641			2,052			1,838
Gain from disposal of equipment		—			—			—			(7	)
Research and development costs		620			603			1,501			1,337
Total operating expenses		1,506			1,366			3,991			3,420
Operating income		1,704			897			4,864			3,818
Interest expense		(58	)		(67	)		(180	)		(156	)
Interest and other income		9			93			77			261
Gain on sale of investments		—			—			—			356
Income from operations before income taxes		1,655			923			4,761			4,279
Income tax expense		(442	)		(191	)		(1,194	)		(1,019	)
Net income	$	1,213		$	732		$	3,567		$	3,260
Other comprehensive income (loss), net of tax:
Unrealized income (loss) from marketable equity investments		(1,262	)		33			(613	)		(163	)
Comprehensive income (loss)	$	(49	)	$	765		$	2,954		$	3,097
Basic net income per share:
Net income	$	0.31		$	0.18		$	0.90		$	0.77
Diluted net income per share:
Net income	$	0.30		$	0.17		$	0.88		$	0.75
Weighted average common shares outstanding:
Basic		3,871			4,143			3,944			4,224
Diluted		3,999			4,257			4,071			4,338
Common shares outstanding		3,837			4,136			3,837			4,136

The accompanying notes are an integral part of these condensed financial statements.

2

PRO-DEX, INC.

CONDENSED STATEMENTS OF SHAREHOLDERS’ EQUITY

For the Three and Nine Months Ended March 31, 2020 and 2019

(Unaudited)

(In thousands)

	Three Months Ended March 31,						Nine Months Ended March 31,
	2020			2019			2020			2019
Common shares:
Balance, beginning of period	$	13,634		$	17,209		$	15,815		$	19,835
Share-based compensation expense		74			10			93			28
Share repurchases		(761	)		(115	)		(2,977	)		(2,675	)
Shares withheld from common stock issued to pay employee payroll taxes		—			—			—			(101	)
Exercise of stock options		—			—			—			7
ESPP shares issued		23			12			39			22
Balance, at end of period	$	12,970		$	17,116		$	12,970		$	17,116
Accumulated other comprehensive income (loss):
Balance, beginning of period	$	100		$	(349	)	$	(549	)	$	(153	)
Net change in unrealized gain (loss) from marketable securities, net of taxes		(1,262	)		33			(613	)		(163	)
Balance, at end of period	$	(1,162	)	$	(316	)	$	(1,162	)	$	(316	)
Retained earnings/(accumulated deficit):
Balance, beginning of period	$	4,138		$	122		$	1,742		$	(2,406	)
Cumulative effect of change in accounting principle		—			—			42			—
Net income		1,213			732			3,567			3,260
Balance, at end of period	$	5,351		$	854		$	5,351		$	854
Total shareholders’ equity	$	17,159		$	17,654		$	17,159		$	17,654

The accompanying notes are an integral part of these condensed financial statements.

3

PRO-DEX, INC.

CONDENSED STATEMENTS OF CASH FLOWS

(Unaudited)

(In thousands)

	Nine Months Ended March 31,
	2020			2019
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income	$	3,567		$	3,260
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization		426			309
Amortization of loan fees		6			5
Gain from disposal of equipment		—			(7	)
Share-based compensation		93			28
Non-cash lease expense		31			—
Gain on sale of investments		—			(356	)
Deferred income taxes		207			1,026
Bad debt expense (recovery)		6			(14	)
Changes in operating assets and liabilities:
Accounts receivable and other current receivables		(76	)		(773	)
Deferred costs		39			(235	)
Inventory		(2,404	)		(412	)
Prepaid expenses and other assets		396			(410	)
Accounts payable and accrued expenses		(301	)		353
Deferred revenue		145			169
Income taxes payable		163			142
Net cash provided by operating activities		2,298			3,085
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of investments		(1,827	)		(2,562	)
Purchases of equipment and leasehold improvements		(422	)		(1,048	)
Proceeds from sale of investments		—			1,905
Proceeds from dividend reclassification as return of principal		15			23
Proceeds from collection of notes receivable		—			1,154
Proceeds from sale of equipment		—			7
Increase in intangibles		(19	)		(11	)
Net cash used in investing activities		(2,253	)		(532	)
CASH FLOWS FROM FINANCING ACTIVITIES:
Repurchases of common stock		(2,977	)		(2,675	)
Proceeds from exercise of options and ESPP contributions		39			29
Payment of employee payroll taxes on net issuance of common stock		—			(101	)
Proceeds from Minnesota Bank & Trust long-term debt, net of fees		—			4,940
Principal payments on notes payable and capital lease		(471	)		(273	)
Net cash provided by (used in) financing activities		(3,409	)		1,920
Net increase (decrease) in cash and cash equivalents		(3,364	)		4,473
Cash and cash equivalents, beginning of period		7,742			5,188
Cash and cash equivalents, end of period	$	4,378		$	9,661

The accompanying notes are an integral part of these condensed financial statements.

4

PRO-DEX, INC.

CONDENSED STATEMENTS OF CASH FLOWS - CONTINUED

(Unaudited)

(In thousands)

	Nine Months Ended March 31,
	2020		2019
Supplemental disclosures of cash flow information:
Cash paid during the period for:
Interest	$	161	$	134
Income taxes	$	382	$	315

The accompanying notes are an integral part of these condensed financial statements.

5

PRO-DEX, INC.

NOTES TO CONSDENSED FINANCIAL STATEMENTS

(UNAUDITED)

NOTE 1. BASIS OF PRESENTATION

The accompanying unaudited condensed financial statements of Pro-Dex, Inc. (“we,” “us,” “our,” “Pro-Dex,” or the “Company”) have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial information and with applicable rules of the Securities and Exchange Commission. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. These financial statements should be read in conjunction with the financial statements presented in our Annual Report on Form 10-K for the fiscal year ended June 30, 2019. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. The results of operations for such interim periods are not necessarily indicative of the results that may be expected for the full year. For further information, refer to the financial statements and footnotes thereto included in our Annual Report on Form 10-K for the year ended June 30, 2019.

Recently Adopted Accounting Standards

On July 1, 2019, we adopted ASU 2016-02 (Topic 842) “Leases,” using a modified retrospective approach through a cumulative effect adjustment to retained earnings as of the beginning of fiscal 2020. The objective of this update is to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. The impact of adoption was an increase to long-term assets and total liabilities each in the amount of approximately $3.3 million as of July 1, 2019.

NOTE 2. DESCRIPTION OF BUSINESS

We specialize in the design, development and manufacture of autoclavable, battery-powered and electric, multi-function surgical drivers and shavers used primarily in the orthopedic and maxocranial facial markets. We have patented adaptive torque-limiting software and proprietary sealing solutions which appeal to our customers, primarily medical device distributors. We also manufacture and sell rotary air motors to a wide range of industries.

NOTE 3. COMPOSITION OF CERTAIN FINANCIAL STATEMENT ITEMS

Inventory

Inventory is stated at the lower of cost (first-in, first-out) or net realizable value and consists of the following (in thousands):

	March 31, 2020		June 30, 2019
Raw materials /purchased components	$	4,113	$	3,132
Work in process		2,574		1,511
Sub-assemblies/finished components		1,662		1,524
Finished goods		294		72
Total inventory	$	8,643	$	6,239

Investments

Investments are stated at market value and consist of the following (in thousands):

	March 31, 2020		June 30, 2019
Marketable equity securities - short-term	$	2,771	$	2,649
Marketable equity securities - long-term		1,659		582
Total marketable equity securities	$	4,430	$	3,231

Investments at March 31, 2020 and June 30, 2019 had an aggregate cost basis of $5,592,000 and $3,780,000, respectively. At March 31, 2020, the investments included net unrealized losses of $1,162,000 (gross unrealized losses of $1,384,000 offset by gross unrealized gains of $222,000). At June 30, 2019, the investments included net unrealized losses of $549,000 and no unrealized gains.

6

PRO-DEX, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(UNAUDITED)

Of the total marketable equity securities at March 31, 2020 and June 30, 2019, $930,000 and $938,000, respectively, represent an investment in the common and preferred stock of Air T, Inc. Two of our Board members are also board members of Air T, Inc. and both either individually or through affiliates own an equity interest in Air T, Inc. Our Chairman, one of the two Board members aforementioned, also serves as the Chief Executive Officer and Chairman of Air T, Inc. The common stock was purchased through 10b5-1 Plans, and the purchased preferred stock was purchased through the exercise of issued warrants and in both cases, in accordance with our internal policies regarding the approval of related party transactions, purchases were approved by our three Board members that are not affiliated with Air T, Inc.

We invest surplus cash from time to time through our Investment Committee, which is comprised of one management director, Mr. Van Kirk, and two non-management directors, Mr. Cabillot and Mr. Swenson, who chairs the committee. Both Mr. Cabillot and Mr. Swenson are active investors with extensive portfolio management expertise. We leverage the experience of these committee members to make investment decisions for the investment of our surplus operating capital or borrowed funds. Additionally, many of our securities holdings include stocks of public companies that either Messrs. Swenson or Cabillot or both may own from time to time either individually or through the investment funds that they manage, or other companies whose boards they sit on, such as Air T, Inc.

Intangibles

Intangibles consist of the following (in thousands):

	March 31, 2020			June 30, 2019
Patent-related costs	$	195		$	175
Less accumulated amortization		(57	)		(46	)
	$	138		$	129

Patent-related costs consist of legal fees incurred in connection with both patent applications and a patent issuance, and will be amortized over the estimated life of the product(s) that is or will be utilizing the technology, or expensed immediately in the event the patent office denies the issuance of the patent. Since we do not know when, or if, our patent applications will be issued, the future amortization expense is not predictable.

NOTE 4. WARRANTY

The warranty accrual is based on historical costs of warranty repairs and expected future identifiable warranty expenses and is included in accrued expenses in the accompanying balance sheets. As of March 31, 2020 and June 30, 2019, the warranty reserve amounted to $173,000 and $136,000, respectively. Warranty expenses are included in cost of sales in the accompanying statements of operations. Changes in estimates to previously established warranty accruals result from current period updates to assumptions regarding repair costs and warranty return rates and are included in current period warranty expense. Warranty expense relating to new product sales and changes to estimates for the three months ended March 31, 2020 and 2019 was $69,000 and $52,000, respectively, and for the nine months ended March 31, 2020 and 2019 was $125,000 and $82,000, respectively.

Information regarding the accrual for warranty costs for the three and nine months ended March 31, 2020 and 2019 are as follows (in thousands):

	As of and for the Three Months Ended March 31,
	2020			2019
Beginning balance	$	141		$	99
Accruals during the period		77			39
Changes in estimates of prior period warranty accruals		(8	)		13
Warranty amortization		(37	)		(15	)
Ending balance	$	173		$	136

7

PRO-DEX, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(UNAUDITED)

	As of and for the Nine Months Ended March 31,
	2020			2019
Beginning balance	$	136		$	107
Accruals during the period		130			93
Changes in estimates of prior period warranty accruals		(5	)		(11	)
Warranty amortization		(88	)		(53	)
Ending balance	$	173		$	136

NOTE 5. NET INCOME PER SHARE

The Company calculates basic net income per share by dividing net income by the weighted-average number of common shares outstanding during the reporting period. The weighted-average number of common shares outstanding used in the calculation of diluted income per share reflects the effects of potentially dilutive securities, in income generating periods, which consist entirely of outstanding stock options and performance awards.

The following table presents reconciliations of the numerators and denominators of the basic and diluted earnings per share computations for net income. In the tables below, income amounts represent the numerator, and share amounts represent the denominator (in thousands, except per share amounts):

	Three Months Ended March 31,				Nine Months Ended March 31,
	2020		2019		2020		2019
Basic:
Net income	$	1,213	$	732	$	3,567	$	3,260
Weighted average shares outstanding		3,871		4,143		3,944		4,224
Basic income per share	$	0.31	$	0.18	$	0.90	$	0.77
Diluted:
Net income	$	1,213	$	732	$	3,567	$	3,260
Weighted average shares outstanding		3,871		4,143		3,944		4,224
Effect of dilutive securities		128		114		127		114
Weighted average shares used in calculation of diluted earnings per share		3,999		4,257		4,071		4,338
Diluted income per share	$	0.30	$	0.17	$	0.88	$	0.75

NOTE 6. INCOME TAXES

Deferred income taxes are provided on a liability method whereby deferred tax assets and liabilities are recognized for temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax basis. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.

Significant management judgment is required in determining our provision for income taxes and the recoverability of our deferred tax assets. Such determination is based primarily on our historical taxable income, with some consideration given to our estimates of future taxable income by jurisdictions in which we operate and the period over which our deferred tax assets would be recoverable.

As of March 31, 2020, we have accrued $489,000 of unrecognized tax benefits related to federal and state income tax matters. None of this balance is expected to reduce our income tax expense if recognized.

8

PRO-DEX, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(UNAUDITED)

A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (in thousands):

	As of and for the Nine Months Ended March 31,
	2020			2019
Beginning balance	$	490		$	462
Additions based on tax positions related to the current year		22			17
Reductions based on tax positions related to prior years		(23	)		—
Ending balance	$	489		$	479

On March 27, 2020, President Trump signed into law the Coronavirus Aid, Relief and Economic Security Act ("CARES Act"). The CARES Act, among other things, includes provisions relating to refundable payroll tax credits, deferment of employer side social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations and technical corrections to tax depreciation methods for qualified improvement property (“QIP”). Under ASC 740, the effects of new legislation are recognized upon enactment.  Accordingly, the effects of the CARES Act are effective for the period ending March 31, 2020. 

As of March 31, 2020, we have, as a result of the technical amendments made by the CARES Act to QIP, accelerated tax depreciation expenses of approximately $92,000 which represents favorable temporary book-to-tax timing differences (i.e., no effective tax rate impact) for income tax purposes and are recorded as components within our deferred income tax assets and income tax receivable, included in prepaid expenses and other current assets, on our condensed consolidated balance sheets. We are continuing to examine additional impacts that the CARES Act may have on our business.

We recognize accrued interest and penalties related to unrecognized tax benefits when applicable. As of March 31, 2020, no interest or penalties applicable to our unrecognized tax benefits have been accrued since we have sufficient tax attributes available to fully offset any potential assessment of additional tax.

We are subject to U.S. federal income tax, as well as income tax of multiple state tax jurisdictions. We are currently open to audit under the statute of limitations by the Internal Revenue Service for the years ended June 30, 2016 and later. Our state income tax returns are open to audit under the statute of limitations for the years ended June 30, 2015 and later. We do not anticipate a significant change to the total amount of unrecognized tax benefits within the next 12 months.

NOTE 7. SHARE-BASED COMPENSATION

Through June 2014, we had two equity compensation plans, the Second Amended and Restated 2004 Stock Option Plan (the “Employee Stock Option Plan”) and the Amended and Restated 2004 Directors’ Stock Option Plan (the “Directors’ Stock Option Plan”) (collectively, the “Former Stock Option Plans”). The Employee Stock Option Plan and Director’s Stock Option Plan were terminated in June 2014 and December 2014, respectively.

In September 2016, our Board approved the establishment of the 2016 Equity Incentive Plan, which was approved by our shareholders at the November 29, 2016 Annual Meeting. The 2016 Equity Incentive Plan provides for the award of up to 1,500,000 shares of our common stock in the form of incentive stock options, nonstatutory stock options, stock appreciation rights, restricted shares, restricted stock units, performance awards, and other stock-based awards. As of March 31, 2020, we have granted performance awards under the 2016 Equity Incentive Plan for up to 200,000 shares of our common stock, of which 40,000 shares have vested as further described below under the heading “Performance Awards.”

9

PRO-DEX, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(UNAUDITED)

Stock Options

No options were granted during the three or nine months ended March 31, 2020 and 2019.

As of March 31, 2020, there was no unrecognized compensation cost under the Former Stock Option Plans, as all outstanding stock options are fully vested. As of March 31, 2020, the options outstanding had a weighted average remaining contractual life of 1.3 years and an intrinsic value of $774,000. Following is a summary of stock option activity for the nine months ended March 31, 2020 and 2019:

	2020				2019
	Number of Shares		Weighted-Average Exercise Price		Number of Shares			Weighted-Average Exercise Price
Outstanding at July 1,		54,000	$	1.86		57,000		$	1.88
Options granted		—		—		—			—
Options exercised		—		—		(3,000	)		2.14
Options forfeited		—		—		—			—
Outstanding at end of period		54,000	$	1.86		54,000		$	1.86
Stock Options Exercisable at March 31,		54,000	$	1.86		54,000		$	1.86

Performance Awards

In December 2017, the Compensation Committee of the Board of Directors granted performance awards to certain of our employees, for an aggregate of up to 200,000 shares of our common stock. Whether any performance awards vest, and the amount that does vest, is tied to the completion of service periods that range from 7 months to 9.5 years and the achievement of our common stock trading at certain pre-determined prices. The weighted average fair value of the performance awards granted in 2017 was $4.46, calculated using the weighted average fair market value for each award, using a Monte Carlo simulation. In February 2020, the Compensation Committee of the Board of Directors reallocated 48,000 previously forfeited awards, having the same remaining terms and conditions, to certain current employees. The weighted average fair value of the performance awards granted in 2020 was $16.90, calculated using the weighted average fair market value for each award, using a Monte Carlo simulation. We recorded share-based compensation expense of $70,000 and $8,000 for the three months ended March 31, 2020 and 2019, respectively, and $86,000 and $24,000 for the nine months ended March 31, 2020 and 2019, respectively, related to these performance awards. On March 31, 2020, there was approximately $437,000 of unrecognized compensation cost related to non-vested performance awards expected to be expensed over the weighted-average period of 3.11 years.

On July 1, 2018, it was determined by the Compensation Committee of our Board of Directors that the first of five tranches of performance awards had been achieved and participants were awarded 40,000 shares of common stock. Each participant elected a net issuance to cover their individual withholding taxes and therefore we issued 24,727 shares of common stock and paid $101,000 of participant related payroll tax liabilities.

Employee Stock Purchase Plan

In September 2014, our Board approved the establishment of an Employee Stock Purchase Plan (the “ESPP”), which was approved by our shareholders at the December 3, 2014 Annual Meeting. The ESPP conforms to the provisions of Section 423 of the Internal Revenue Code, has coterminous offering and purchase periods of six months, and bases the pricing to purchase shares of our common stock on a formula so as to result in a per share purchase price that approximates a 15% discount from the market price of a share of our common stock at the end of the purchase period. Our Board of Directors also approved the provision that shares formerly reserved for issuance under the Former Stock Option Plans in excess of shares issuable pursuant to outstanding options under those plans, aggregating 704,715 shares, be reserved for issuance pursuant to the ESPP.

During the three months ended March 31, 2020 and 2019, we recorded share-based compensation expense in the amount of $4,000 and $2,000, respectively, and 1,628 and 923 shares were purchased, respectively, and allocated to employees based upon their contributions at prices of $14.43 and $12.96, respectively, per share. During the nine months ended March 31, 2020 and 2019, we recorded share-based compensation expense in the amount of $7,000 and $4,000, respectively, relating to the ESPP. On a cumulative basis, since the inception of the ESPP, employees have purchased a total of 21,786 shares of our common stock.

10

PRO-DEX, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(UNAUDITED)

NOTE 8. MAJOR CUSTOMERS AND SUPPLIERS

Information with respect to customers that accounted for sales in excess of 10% of our total sales in either of the three-month and the nine-month periods ended March 31, 2020 and 2019 is as follows (in thousands, except percentages):

	Three Months Ended March 31,
	2020					2019
	Amount		Percent of Total			Amount		Percent of Total
Net sales	$	8,508		100	%	$	6,854		100	%
Customer concentration:
Customer 1	$	5,373		63	%	$	4,116		60	%
Customer 2		2,337		28	%		1,077		16	%
Customer 3		428		5	%		905		13	%
Total	$	8,138		96	%	$	6,098		89	%

	Nine Months Ended March 31,
	2020					2019
	Amount		Percent of Total			Amount		Percent of Total
Net sales	$	23,710		100	%	$	20,168		100	%
Customer concentration:
Customer 1		16,440		69	%		12,556		62	%
Customer 2		3,458		15	%		2,601		13	%
Total	$	19,898		84	%	$	15,157		75	%

Information with respect to accounts receivable from those customers who comprised more than 10 % of our gross accounts receivable at either March 31, 2020 or June 30, 2019 is as follows (in thousands, except percentages):

	March 31, 2020				June 30, 2019
Total gross accounts receivable	$	4,176	100	%	$	4,100	100	%
Customer concentration:
Customer 1	$	1,772	42	%	$	2,587	63	%
Customer 2		1,975	47	%		780	19	%
Total	$	3,747	89	%	$	3,367	82	%

During the three and nine months ended March 31, 2020, we had three suppliers accounting for 10% or more of total inventory purchases. During the three and nine months ended March 31, 2019, we had one supplier that accounted for more than 10% of our total inventory purchases. Amounts owed to the fiscal 2020 significant suppliers at March 31, 2020 and June 30, 2019 is as follows (in thousands, except percentages).

	March 31, 2020				June 30, 2019
Total accounts payable	$	1,912	100	%	$	1,996	100	%
Supplier concentration:
Portescap	$	133	7	%	$	373	19	%
Fischer Connectors, Inc.		183	10	%		304	15	%
Tadiran Batteries		163	8	%		142	7	%
Total	$	479	25	%	$	819	41	%

11

PRO-DEX, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(UNAUDITED)

NOTE 9. NOTES PAYABLE AND FINANCING TRANSACTIONS

Minnesota Bank & Trust

On September 6, 2018, we entered into a Credit Agreement with Minnesota Bank & Trust, a Minnesota state banking corporation (“MBT”), providing for a $5,000,000 term loan (the “Term Loan”) as well as a $2,000,000 revolving loan (the “Revolving Loan” and together with the Term Loan, collectively the “Loans”), evidenced by a Term Note A and a Revolving Credit Note made by us in favor of MBT. The Loans are secured by substantially all of our assets pursuant to a Security Agreement entered into on September 6, 2018 between us and MBT. We paid loan origination fees to MBT in the amount of $60,000.

The Term Loan matures on October 1, 2025 and bears interest at a fixed rate of 5.53% per annum. An initial payment of interest only in the amount of $18,433 was paid on October 1, 2018. Commencing November 1, 2018 and continuing on the first day of each subsequent month thereafter until the maturity date, we are required to make payments of principal and interest on the Term Loan of approximately $72,000, plus any additional accrued and unpaid interest through the date of payment. The balance owed on the Term Loan at March 31, 2020 is $4.1 million, net of unamortized loan fees. The Revolving Loan had an original maturity date of September 6, 2019, which has since been extended to November 6, 2020, and bears interest at the greater of (a) 4.5% or (b) the difference of the prime rate as published in the Money Rates section of the Wall Street Journal minus 0.50%. Commencing on the first day of each month after we initially borrow against the Revolving Loan, which we have yet to do, and each month thereafter until maturity, we are required to pay all accrued and unpaid interest on the Revolving Loan through the date of payment. Any principal on the Revolving Loan that is not previously prepaid shall be due and payable on the maturity date (or earlier termination of the Revolving Loan). As we have yet to borrow under the Revolving Loan, the balance owed under it at March 31, 2020 was $0.

Any payment on the Loans not made within seven days after the due date is subject to a late payment fee equal to 5% of the overdue amount. Upon the occurrence and during the continuance of an event of default, the interest rate of both Loans will be increased by 3% and MBT may, at its option, declare the Loans immediately due and payable in full.

The Credit Agreement and Security Agreement contain representations and warranties, affirmative, negative and financial covenants, and events of default that are customary for loans of this type.

NOTE 10. COMMON STOCK

Share Repurchase Program

In December 2019, our Board approved a new share repurchase program authorizing us to repurchase up to 1 million shares of our common stock, as the prior repurchase plan authorized by our Board in 2013 was nearing completion. In accordance with, and as part of, these share repurchase programs, our Board approved the adoption of several prearranged share repurchase plans intended to qualify for the safe harbor provided by Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (“10b5-1 Plan” or “Plan”). During the three and nine months ended March 31, 2020, we repurchased 48,236 and 204,921 shares, respectively, at an aggregate cost, inclusive of fees under the plan, of $761,000 and $2,977,000, respectively. During the three and nine months ended March 31, 2019 we repurchased 7,914 and 225,368 shares, respectively at an aggregate cost, inclusive of fees under the plan, of $115,000 and $2,675,000, respectively. On a cumulative basis, since implementation of the share repurchase program in 2013, we have repurchased a total of 792,972 shares under the share repurchase program at an aggregate cost of $8.1 million. All repurchases under the 10b5-1 Plans were administered through an independent broker.

At The Market Offering Agreement

In February 2017, our Board approved an ATM Agreement with Ascendiant Capital Markets, LLC (“Ascendiant”). The ATM Agreement allowed us to sell shares of our common stock pursuant to specific parameters defined by us as well as those defined by the SEC and the ATM Agreement. During the three and nine months ended March 31, 2020 and 2019 we did not issue any shares under the ATM. From the inception of the ATM in February 2017 through December 31, 2017, during periods when we did not make purchases under our share repurchase program, we sold 340,465 shares of common stock for gross proceeds of $2,311,000 net of commissions and fees paid to Ascendiant totaling $72,000. In December 2017, the Board suspended the ATM indefinitely and the ATM expired, pursuant to its terms, in February 2020.

12

PRO-DEX, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(UNAUDITED)

NOTE 11. LEASES

Effective July 1, 2019, we adopted the new lease accounting standard using the modified retrospective method of applying the new standard at the adoption date. In addition, we elected the practical expedient which allowed us to carry forward the historical lease classification of our sole operating lease for our corporate office, which includes our manufacturing and research and development facilities. Adoption of this standard resulted in the recording of net operating lease right-of-use (“ROU”) asset and corresponding operating lease liability each in the amount of $3.3 million. Our financial position for reporting periods beginning on or after July 1, 2019 is presented under the new guidance, while prior period amounts are not adjusted and continue to be reported in accordance with previous guidance.

Our operating lease ROU asset and long-term liability are presented separately on our Condensed Balance Sheet. The current portion of our operating lease liability as of March 31, 2020, in the amount of $304,000, is presented within accrued expenses on the Condensed Balance Sheet.

As of March 31, 2020, the maturity of our lease liability is as follows:

	Operating Lease
Fiscal Year:
2020	$	116
2021		475
2022		489
2023		504
2024		519
Thereafter		1,796
Total lease payments		3,899
Less imputed interest:		(738	)
Total	$	3,161

As of March 31, 2020, our operating lease has a remaining lease term of seven years and six months and an imputed interest rate of 5.3%. Cash paid for amounts included in the lease liability for the three and nine months ended March 31, 2020 was $116,000 and $345,000, respectively. As previously disclosed in our 2019 Annual Report on Form 10-K and under the previous lease accounting standard, future minimum lease payments for our only operating lease having an initial or remaining noncancellable lease term in excess of one year would have been as follows:

	Operating Leases at June 30, 2019
Fiscal Year:
2020	$	461
2021		475
2022		489
2023		504
2024		519
Thereafter		1,796
Total minimum lease payments	$	4,244

NOTE 12. COMMITMENTS AND CONTINGENCIES

Legal Matters

We are from time to time a party to various legal proceedings incidental to our business. There can be no certainty, however, that we may not ultimately incur liability or that such liability will not be material and adverse.

13

PRO-DEX, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(UNAUDITED)

NOTE 13. SUBSEQUENT EVENT

On April 7, 2020, as reported in our Current Report filed with the SEC on April 14, 2020, we entered into a Paycheck Protection Program Loan (the “PPP Loan”) sponsored by the Small Business Administration (“SBA”) through MBT, providing for $1,360,100 in proceeds, which amount was funded to the Company on April 10, 2020. The PPP Loan was made pursuant to the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”). We repaid the loan on May 5, 2020, after careful consideration of additional guidance issued by the SBA and the Department of Treasury.

14

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis should be read in conjunction with our unaudited interim condensed financial statements and the related notes and other financial information appearing elsewhere in this report.

COMPANY OVERVIEW

The following discussion and analysis provides information that management believes is relevant to an assessment and understanding of the results of operations and financial condition of Pro-Dex, Inc. (“Company,” “Pro-Dex,” “we,” “our,” or “us”) for the three-month and nine-month periods ended March 31, 2020 and 2019. This discussion should be read in conjunction with the condensed financial statements and the notes thereto included elsewhere in this report. This report contains certain forward-looking statements and information. The cautionary statements included herein should be read as being applicable to all related forward-looking statements wherever they may appear. Our actual future results could differ materially from those discussed herein.

Except for the historical information contained herein, the matters discussed in this report, including, but not limited to, discussions of our product development plans, business strategies, strategic opportunities and market factors influencing our results, including uncertainties related to the COVID-19 pandemic, are forward-looking statements that involve certain risks and uncertainties. Actual results may differ from those anticipated by us as a result of various factors, both foreseen and unforeseen, including, but not limited to, our ability to continue to develop new products and increase sales in markets characterized by rapid technological evolution, consolidation within our target marketplace and among our competitors, competition from larger, better capitalized competitors, impacts of the COVID-19 pandemic on us or our business partners, including our customers and suppliers, and our ability to realize returns on opportunities. Many other economic, competitive, governmental and technological factors could impact our ability to achieve our goals. You are urged to review the risks, uncertainties and other cautionary language described in this report, as well as in our other public disclosures and reports filed with the Securities and Exchange Commission (“SEC”) from time to time, including, but not limited to, the risks, uncertainties and other cautionary language discussed in our Annual Report on Form 10-K for our fiscal year ended June 30, 2019.

We specialize in the design, development and manufacture of autoclavable, battery-powered and electric, multi-function surgical drivers and shavers used primarily in the orthopedic, maxocranial, and thoracic markets. We have patented adaptive torque-limiting software and proprietary sealing solutions which appeal to our customers, primarily medical device distributors. We also manufacture and sell rotary air motors to a wide range of industries.

Our principal headquarters are located at 2361 McGaw Avenue, Irvine, California 92614 and our phone number is (949) 769-3200. Our Internet address is www.pro-dex.com. Our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, amendments to those reports and other SEC filings are available free of charge through our website as soon as reasonably practicable after such reports are electronically filed with, or furnished to, the SEC. In addition, our Code of Ethics and other corporate governance documents may be found on our website at the Internet address set forth above. Our filings with the SEC may also be read and copied at the SEC’s Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549. You may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. The SEC maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC at www.sec.gov and company specific information at www.sec.gov/edgar/searchedgar/companysearch.html.

Basis of Presentation

The condensed results of operations presented in this report are not audited and those results are not necessarily indicative of the results to be expected for the entirety of the fiscal year ending June 30, 2020 or any other interim period during such fiscal year. Our fiscal year ends on June 30 and our fiscal quarters end on September 30, December 31, and March 31. Unless otherwise stated, all dates refer to our fiscal year and those fiscal quarters.

Critical Accounting Estimates and Judgments

Our financial statements are prepared in accordance with accounting principles generally accepted in the United States. The preparation of our financial statements requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, expenses and related disclosures. We base our estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates.

15

An accounting policy is deemed to be critical if it requires an accounting estimate to be made based on assumptions about matters that are highly uncertain at the time the estimate is made, and if different estimates that reasonably could have been used or changes in the accounting estimate that are reasonably likely to occur could materially change the financial statements. Management believes that there have been no significant changes during the three and nine months ended March 31, 2020, other than the required adoption of ASU 2016-02 (Topic 842), Leases, to the items that we disclosed as our critical accounting policies in Management’s Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the fiscal year ended June 30, 2019.

COVID-19 Pandemic

As publicly noted in a press release dated March 24, 2020, we are continuing our business operations under an exemption from California Governor Newsom’s Executive Order N-33-20 (issued March 19, 2020) for “essential critical infrastructure sectors” based on our determination that we fall within the Healthcare and Public Health Sector exemption.

As we continue to operate, we have adjusted certain policies and procedures based on applicable national, state, and local emergency orders and safety guidance that may be issued from time to time, including:

· Non-essential employees that are able to work remotely are doing so;

· Increased frequency of disinfectant cleanings, especially for high-touch surfaces;

· Curtailed business travel;

· Multiple, staggered work shifts have been implemented in order to achieve effective social distancing; and

· Provided training, education and appropriate personal protective equipment.

While we have yet to see any decline in our customer orders, we have received and accepted some customer requests to delay the shipment of their existing orders. We provide our largest customer with a device used primarily in elective surgeries and although this customer has not requested a reduction or delay to their planned shipments, if this pandemic continues to adversely impact the United States and other markets where our products are sold, coupled with the recommended deferrals of elective procedures by governments and other authorities, we would expect to see a decline in demand from our principal customer.

We are focused on the health and safety of all those we serve – our customers, our communities, our employees, and our suppliers. We are supporting our customers according to their priorities and working with them to the degree that we can offer relief in the form of delayed shipments. We are focused on continuity of supply by working with our suppliers.

While the COVID-19 pandemic did not materially adversely affect our financial results and business operations in our third fiscal quarter ended March 31, 2020, economic and health conditions in the United States and across much of the globe have changed rapidly since the end of the quarter, and we cannot predict the full impact of the COVID-19 pandemic on our business.

Business Strategy and Future Plans

Our business today is almost entirely driven by sales of our medical devices. Many of our significant customers place purchase orders for specific products that were developed under various development and/or supply agreements. Our customers may request that we design and manufacture a custom surgical device or they may hire us as a contract manufacturer to manufacture a product of their own design. In either case, we have extensive experience with autoclavable, battery-powered and electric, multi-function surgical drivers and shavers. We continue to focus a significant percentage of our time and resources on providing outstanding products and service to our valued principal customers.

Our patented adaptive torque-limiting software has been very well received in the CMF market and we have continued investment in this area with research and development focused on applying this technology to thoracic surgical applications. We have invested significantly since fiscal 2018 on a thoracic driver utilizing adaptive torque-limiting software, and in early fiscal 2019 entered a development contract with an existing significant customer to private-label this driver for their unique specifications and we shipped this new driver, batteries and accessories during the third quarter ended March 31, 2020.

16

In summary, our current objectives are focused primarily on maintaining our relationships with our current medical device customers, investing in research and development activities to design Pro-Dex branded drivers to leverage our torque-limiting software, and promoting active product development proposals to new and existing customers for both orthopedic shavers and screw drivers for a multitude of surgical applications, while monitoring closely the progress of all these individual endeavors. Our research and development, selling and general and administrative expenses have, in recent periods, increased disproportionately to our growth in revenue as we focus on new product development and we anticipate this to continue in the near term. These expenditures are being made in an effort to release new products and garner new customer relationships. While we expect revenue growth in the future, it may not be a consistent trajectory, but rather periods of incremental growth that current expenditures are helping to create. However, there can be no assurance that we will be successful in any of these objectives.

Description of Business Operations

Revenue

The majority of our revenue is derived from designing, developing and manufacturing surgical devices for the medical device industry. The proportion of total sales by type is as follows (in thousands, except percentages):

	Three Months Ended March 31,										Nine Months Ended March 31,
	2020					2019					2020					2019
			% of Revenue					% of Revenue					% of Revenue					% of Revenue
Net Sales:
Medical device products	$	6,656		78	%	$	6,297		92	%	$	18,148		76	%	$	18,602		92	%
Industrial and scientific		140		2	%		205		3	%		485		2	%		689		3	%
Dental and component		91		1	%		101		2	%		185		1	%		340		2	%
NRE & Proto-type		190		2	%		24		—			457		2	%		156		1	%
Repairs and other		1,431		17	%		227		3	%		4,435		19	%		381		2	%
	$	8,508		100	%	$	6,854		100	%	$	23,710		100	%	$	20,168		100	%

Certain of our medical device products utilize proprietary designs developed by us under exclusive development and supply agreements. All of our medical device products utilize proprietary manufacturing methods and know-how, and are manufactured in our Irvine, California facility, as are our industrial products.

Sales of our medical device products increased $0.4 million, or 6%, for the three months ended March 31, 2020 and decreased $0.5 million, or 2%, for the nine months ended March 31, 2020 compared to the corresponding periods of the prior fiscal year. Our medical device revenue to our largest customer increased $69,000 and decreased $186,000, respectively, for the three and nine months ended March 31, 2020 compared to the corresponding periods of the prior fiscal year, due to contractual price concessions offset by slight volume increases. Additionally, during the third quarter ended March 31, 2020, we completed the private-label effort for our thoracic driver and initial shipments to our customer in the third quarter totaled $1.5 million. Offsetting this increase from the launch of the thoracic driver, revenue from two legacy medical device customers decreased approximately $256,000 and $1.2 million, respectively, for the three and nine months ended March 31, 2020 compared to the corresponding periods of the prior fiscal year. Additionally, recurring revenue from two significant distributors of CMF drivers had combined decreases in sales for the three and nine months ended March 31, 2020 of $946,000 and $612,000, respectively, compared to the corresponding periods of the prior fiscal year.

Sales of our compact pneumatic air motors, reported as Industrial and scientific sales above, decreased $65,000, or 32%, and $204,000, or 30%, respectively, for the three and nine months ended March 31, 2020 compared to the corresponding periods of the prior fiscal year. The revenue decline relates to a lack of marketing efforts for these legacy products.

Sales of our dental products and components declined for the three and nine months ended March 31, 2020 compared to the corresponding periods of the prior fiscal year and we expect future declines in this area as we are no longer manufacturing dental products, but rather are simply selling remaining component inventory. As previously discussed, in January 2018, we sent notification to our dental product customers that we were discontinuing the manufacture of these products. The cessation of our dental line of products is not expected to have a material impact on our financial position or results of operations and reflected a conscious decision to increase capacity for our medical device products.

17

Repair revenue increased $1.2 million and $4.1 million for the three and nine months ended March 31, 2020, respectively, compared to the corresponding periods of the prior fiscal year due to increased repairs of the orthopedic handpiece we sell to our largest customer. Typically, upon initial product launch, repair revenue is minimal as most repairs are typically covered under warranty, but as the products mature in the marketplace and after a certain number of routine duty cycles in the operating room, repairs generally increase. We expect repair revenue for the remaining quarter of fiscal 2020 to be comparable to the revenue generated during the quarter ended March 31, 2020.

At March 2020, we had a backlog of approximately $14.8 million, of which $10.8 million is scheduled to be delivered in the fourth quarter of fiscal 2020 and the balance is scheduled to be delivered next fiscal year. The backlog for the fourth quarter includes the balance in the amount of $2.3 million from the initial order of the thoracic driver and related accessories to our customer, and while we will endeavor to meet all scheduled deliveries, some of these items may not ship until the first quarter of fiscal 2021. Our backlog represents firm purchase orders received and acknowledged from our customers and does not include all revenue expected to be generated from existing customer contracts. We may experience variability in our new order bookings due to various reasons, including, but not limited to, the timing of major new product launches and customer planned inventory builds. However, we do not typically experience seasonal fluctuations in our shipments and revenues.

Cost of Sales and Gross Margin
(in thousands except percentages)

	Three Months Ended March 31,												Nine Months Ended March 31,
	2020						2019						2020						2019
				% of Total						% of Total						% of Total					% of Total
Cost of sales:
Product cost	$	5,284			99	%	$	4,538			99	%	$	14,781			99	%	$	12,608		97	%
Under(over)-absorption of manufacturing costs		(53	)		—			(13	)		—			(51	)		—			82		1	%
Inventory and warranty charges		67			1	%		66			1	%		125			1	%		240		2	%
Total cost of sales	$	5,298			100	%	$	4,591			100	%	$	14,855			100	%	$	12,930		100	%

	Three Months Ended March 31,						Nine Months Ended March 31,						Year over Year ppt Change
	2020			2019			2020			2019			Three Months		Nine Months
Gross margin		38	%		33	%		37	%		36	%		5		1

Cost of sales for the three months ended March 31, 2020 increased $707,000, or 15%, compared to the corresponding period of the prior fiscal year. The increase in total costs of sales is caused by the 24% increase in revenue for the same period. Under-absorption of manufacturing costs increased by $40,000 for the three months ended March 31, 2020 compared to the corresponding period of the prior fiscal year due primarily to adjustments made to our standard labor and overhead rates at the beginning of fiscal 2020 in anticipation of higher spending in our machine shop and quality departments. Costs relating to inventory and warranty charges remained flat for the third quarter ended March 31, 2020 compared to the third quarter of the prior fiscal year.

Gross profit increased by approximately $947,000, or 42%, for the three months ended March 31, 2020 compared to the corresponding period of the prior fiscal year, primarily due to the thoracic driver product launch, which is a higher margin product due in part to the demand in the marketplace for adaptive torque limiting. Gross margin as a percentage of sales increased by approximately 5 percentage points compared to the corresponding period of the prior fiscal year due primarily to the increased revenue, which allows us to better absorb our fixed manufacturing costs.

Cost of sales for the nine months ended March 31, 2020 increased by $1.9 million, or 15%, compared to the corresponding period of the prior fiscal year, consistent with the increased revenue of 18% for the same period, the reasons for which are discussed above. Additionally, total cost of sales reflects a $133,000 decrease in under-absorbed manufacturing costs. We adjusted our standard labor and over-head rates at the beginning of fiscal 2020 in anticipation of higher spending in our machine shop and quality departments. Inventory and warranty charges decreased by approximately $115,000, or 48%, for the nine months ended March 31, 2020, compared to the corresponding period of the prior fiscal year, due to decreased scrap and inventory charges in the amount of $148,000 offset by increased warranty expenses of $33,000.

18

Gross profit increased by $1.6 million, or 22%, for the nine months ended March 31, 2020 compared to the corresponding period of the prior fiscal year, primarily as a result of the increase in repair revenue discussed above as well as the launch of the thoracic driver in the third quarter of fiscal 2020. Gross margin for the nine months ended March 31, 2020 increased by 1 percentage point compared to the corresponding period of the prior fiscal year, primarily due to increased revenue, as described above.

Operating Expenses

Operating Costs and Expenses
(in thousands except % change)

	Three Months Ended March 31,										Nine Months Ended March 31,										Year over Year % Change
	2020					2019					2020					2019					Three Months			Nine Months
			% of Net Sales					% of Net Sales					% of Net Sales					% of Net Sales
Operating expenses:
Selling expenses	$	161		2	%	$	122		2	%	$	438		2	%	$	252		1	%		32	%		74	%
General and administrative expenses		725		9	%		641		9	%		2,052		9	%		1,838		9	%		13	%		12	%
Research and development costs		620		7	%		603		9	%		1,501		6	%		1,337		7	%		3	%		12	%
	$	1,506		18	%	$	1,366		20	%	$	3,991		17	%	$	3,427		17	%		10	%		17	%

Selling expenses consist of salaries and other personnel-related expenses for our business development department, as well as advertising and marketing expenses, and travel and related costs incurred in generating and maintaining our customer relationships. Selling expenses for the three and nine months ended March 31, 2020 increased $39,000, or 32%, and $186,000, or 74%, respectively, compared to the corresponding periods of fiscal 2019. These increases relate primarily to personnel-related expenses as we filled the previously vacant position of Director of Business Development during the first quarter of fiscal 2019.

General and administrative expenses (“G&A”) consists of salaries and other personnel-related expenses of our accounting, finance and human resource personnel, as well as costs for outsourced information technology services, professional fees, directors’ fees, and other costs and expenses attributable to being a public company. G&A increased $84,000 and $214,000, respectively, during the three and nine months ended March 31, 2020 when compared to the corresponding periods of the prior fiscal year. The increases relate primarily to increased personnel-related expenses, increased equity compensation due to the reallocation of previously forfeited performance awards and increased audit fees.

Research and development costs generally consist of salaries, employer paid benefits, and other personnel related costs of our engineering and support personnel, as well as allocated facility and information technology costs, professional and consulting fees, patent-related fees, lab costs, materials, and travel and related costs incurred in the development and support of our products. Research and development costs for the three and nine months ended March 31, 2020 increased $17,000 and $164,000, respectively, compared to the corresponding periods of the prior fiscal year. These increases are primarily due to increased personnel-related expense offset by decreased spending on internal development projects.

19

Although the majority of our research and development costs relate to sustaining activities related to products we currently manufacture and sell, we have created a product roadmap to develop future products. The research and development costs represent between 38% and 44% of total operating expenses for all periods presented and are expected to increase in the future as we continue to invest in the business. The amount spent on projects under development is summarized below (in thousands):

	Three and Nine Months ended March 31, 2020				Three and Nine Months ended March 31, 2019				Market Launch		Est Annual Revenue
Total Research & Development costs:	$	620	$	1,501	$	603	$	1,337
Products in development:
Arthroscopic Shaver(1)		—		11		160		221		06/21	$	600
ENT Shaver		136		291		—		—		01/21	$	2,000
Arthroscopic Attachment		—		—		1		17		(2)	$	150
CMF Driver		60		106		—		3		06/20	$	350
Sustaining & Other		424		1,093		442		1,096
Total	$	620	$	1,501	$	603	$	1,337
Customer CMF Driver (3)	$	121	$	303	$	63	$	289		06/20	$	2,500

———————

(1)	This project has been internally pushed back to focus on our new internal Pro-Dex branded ENT shaver.
(2)	Internal development of this project is now complete, but we are looking for the most attractive sales channel.
(3)	Costs incurred related to customer contracts are included in costs of sales and deferred costs and are not included in research and development costs.

As we previously discussed, in early fiscal 2019 we entered a development contract with a current significant customer to private-label our thoracic driver for their unique specifications. We shipped initial launch quantities of this product during the third quarter ended March 31, 2020.

Interest & Other Income

Interest income for the three and nine months ended March 31, 2020 includes interest and dividends from our money market accounts and investment portfolio. During the three and six months ended December 31, 2019 we also recorded $8,500 and $17,000, respectively, of miscellaneous income related to cash collected related to note receivable extensions granted on a note we previously wrote off. The fiscal 2019 interest income related primarily to a loan participation note receivable that has since been paid in full, as well as approximately $4,000 and $43,000, respectively, for the three and nine months ended March 31, 2019 in interest and dividend income from our money market accounts and investments.

Interest Expense

Interest expense consists primarily of interest expense related to the notes payable described more fully in Note 9 to the condensed financial statements contained elsewhere in this report and capital lease obligations for leased equipment.

Gain on Sale of Investments

During the quarter ended December 31, 2018, we liquidated one of the stocks in our portfolio of equity investments receiving proceeds of $1.9 million and recording a gain on the sale in the amount of $356,000.

Income Tax Expense

The effective tax rate for the three and nine months ended March 31, 2020 and 2019 is slightly less than our combined expected federal and applicable state corporate income tax rates due to federal and state research credits and the new foreign-derived intangible income deduction.

20

Liquidity and Capital Resources

Cash and cash equivalents at March 31, 2020 decreased $3.3 million to $4.4 million as compared to $7.7 million at June 30, 2019. The following table includes a summary of our condensed statements of cash flows contained elsewhere in this report.

	As of and For the Nine Months Ended March 31,
	2020			2019
	(in thousands)
Cash provided by (used in):
Operating activities	$	2,298		$	3,085
Investing activities	$	(2,253	)	$	(532	)
Financing activities	$	(3,409	)	$	1,920
Cash and Working Capital:
Cash and cash equivalents	$	4,378		$	9,661
Working Capital	$	16,140		$	18,310

Operating Activities

Net cash provided by operating activities was $2.3 million for the nine months ended March 31, 2020 primarily due to net income of $3.6 million and non-cash depreciation and amortization of $426,000. Our inventory increased by $2.4 million primarily related to the thoracic driver that we began shipping during our third quarter ended March 31, 2020 as well as another customer CMF driver we plan to launch in the fourth quarter of fiscal 2020.

Net cash provided by operating activities was $3.1 million for the nine months ended March 31, 2019 primarily due net income of $3.3 million and non-cash depreciation and amortization totaling $309,000. Uses of cash arose from an increase in accounts receivable of $773,000 as well as an increase in deferred costs related to the development of a CMF driver for one of our existing customers in the amount of $235,000. Offsetting these uses of cash was a decrease in deferred taxes in the amount of $1.0 million.

Investing Activities

Net cash used in investing activities for the nine months ended March 31, 2020 was $2.3 million and related to investments in marketable equity securities of publicly traded companies in the amount of $1.8 million and purchases of machinery and equipment in the amount of $422,000.

Net cash used in investing activities for the nine months ended March 31, 2019 was $532,000 and related to investments in marketable equity securities of publicly traded companies in the amount of $2.6 million as well as capital expenditures primarily for manufacturing equipment in the amount of $1.0 million, offset by the sale of one of the securities in our portfolio of common stock of publicly traded companies in the amount of $1.9 million and the collection of $1.2 million from a loan participation note receivable.

Financing Activities

Net cash used in financing activities for the nine months ended March 31, 2020 totaled $3.4 million and related primarily to the $3.0 million repurchase of 204,921 shares of our common stock pursuant to our share repurchase program as well as $471,000 of principal payments on our term loan from Minnesota Bank and Trust (“MBT”) more fully described in Note 9 to the condensed financial statements contained elsewhere in this report.

Net cash provided by financing activities for the nine months ended March 31, 2019 included $5.0 million in a term loan from MBT more fully described in Note 9 to the condensed consolidated financial statements contained elsewhere in this report, offset by $273,000 of principal payments on the MBT term loan and an equipment lease as well as $2.7 million related to the repurchase of 225,368 shares of our common stock pursuant to our share repurchase program.

21

Financing Facilities & Liquidity Requirements for the next twelve months

As of March 31, 2020, our working capital was $16.1 million. We currently believe that our existing cash and cash equivalent balances together with our accounts receivable balances will provide us sufficient funds to satisfy our cash requirements as our business is currently conducted for at least the next 12 months. In addition to our cash and cash equivalent balances, we expect to derive a portion of our liquidity from our cash flows from operations. We may also borrow against our $2.0 million Revolving Loan with MBT (See Note 9 to condensed financial statements contained elsewhere in this report).

We are focused on preserving our cash balances by monitoring expenses, identifying cost savings, and investing only in those development programs and products that we believe will most likely contribute to our profitability. As we execute on our current strategy, however, we may require debt and/or equity capital to fund our working capital needs and requirements for capital equipment to support our manufacturing and inspection processes. In particular, we have experienced negative operating cash flow in the past, especially as we procure long-lead time materials to satisfy our backlog, which can be subject to extensive variability.

Investment Strategy

Pro-Dex invests surplus cash from time to time through its Investment Committee which was formed in April 2013.The committee is comprised of one management director, Richard L. Van Kirk, our CEO, and two non-management directors, Raymond E. Cabillot and Nicholas J. Swenson, who chairs the committee. Both Mr. Cabillot and Mr. Swenson are active investors with extensive portfolio management expertise. We leverage the experience of these committee members to make investment decisions for the investment of our surplus operating capital or borrowed funds. Additionally, many of our securities holdings include stocks of public companies that either Messrs. Swenson or Cabillot or both may own from time to time either individually or through the investment funds that they manage, or other companies whose boards they sit on. The Investment Committee approved each of the investments comprising the $4.4 million of marketable public equity securities held at March 31, 2020.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not applicable.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Our Chief Executive Officer and Chief Financial Officer (the principal executive officer and principal financial officer, respectively) conducted an evaluation of the design and operation of our “disclosure controls and procedures” (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (“Exchange Act”)). The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act means controls and other procedures of a company that are designed to ensure that information required to be disclosed by the Company in the reports it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures also include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure.

In accordance with SEC rules, an evaluation was performed under the supervision and with the participation of our Principal Executive Officer and Principal Financial Officer of the effectiveness, as of March 31, 2020, of the Company’s disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act). “Internal control over financial reporting” includes those policies and procedures that: 

(1) pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the issuer;

22

(2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the issuer are being made only in accordance with authorizations of management and directors of the issuer; and

(3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the issuer’s assets that could have a material effect on the financial statements. 

Based on that evaluation as of March 31, 2020, our Chief Executive Officer and Chief Financial Officer concluded that the disclosure controls and procedures are effective.

Internal Control over Financial Reporting

During the three months ended March 31, 2020, there were no changes in our internal controls over financial reporting (as defined in Rule 13a-15(f) and 15d-15(f) under the Exchange Act) that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.

Inherent Limitations on the Effectiveness of Controls

In designing and evaluating our disclosure controls and procedures, our management recognized that any system of controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, as ours are designed to do, and management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risks that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

23

PART II — OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

See Note 12 of Notes to condensed financial statements contained elsewhere in this report.

ITEM 1A. RISK FACTORS

Our business, future financial condition and results of operations are subject to a number of factors, risks and uncertainties, which are disclosed in Item 1A, entitled “Risk Factors” in Part I of our Annual Report on Form 10-K for our fiscal year ended June 30, 2019 as well as any amendments thereto or additions and changes thereto contained in this quarterly report on Form 10-Q for the quarter ended March 31, 2020. Additional information regarding some of those risks and uncertainties is contained in the notes to the condensed financial statements included elsewhere in this report and in Item 2, entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Part I of this report. The risks and uncertainties disclosed in our Form 10-K, our quarterly reports on Form 10-Q and other reports filed with the SEC are not necessarily all of the risks and uncertainties that may affect our business, financial condition and results of operations in the future.

There have been no material changes to the risk factors as disclosed in our annual report on Form 10-K for the fiscal year ended June 30, 2019, except as provided in any amendments thereto and those set forth below.

The COVID-19 Pandemic, or the perception of its effects, could have a material adverse effect on our business and results of operations.

To date, COVID-19 has not had a material adverse impact on our business or results of operations, but due to the uncertainties surrounding this pandemic, it may adversely impact us in the future. We may experience disruptions in our supply chain and critical suppliers may delay or be unable to deliver products we have ordered. Additionally, our customers could reduce planned orders, request cancelations of existing orders and/or delay payment to us due to financial hardship they may experience as a result of this healthcare and resulting economic crisis. Therefore, it is impossible at this time to predict the ultimate short-term or long-term impact of the pandemic on our business.

The ability of our employees to work may be significantly impacted by the COVID-19 crisis.

Our employees are being affected by the COVID-19 pandemic. Some of our office and management personnel are working remotely, but our employees engaged in manufacturing and assembly are continuing to work at our corporate headquarters. The health of our workforce is of primary concern and we may need to enact further precautionary measures to help minimize the risk of our employees being exposed to the coronavirus. Further, our management team is focused on mitigating the adverse effects of the COVID-19 pandemic, which has required and will continue to require a large investment of time and resources across the entire Company, thereby diverting their attention from other priorities that existed prior to the outbreak of the pandemic. If these conditions worsen, or last for an extended period of time, our ability to manage our business may be impaired, and operational risks, cybersecurity risks and other risks facing us even prior to the pandemic may be elevated.

Late in the third quarter of fiscal 2020, we invested an additional approximately $450,000 in marketable securities. Should our investments decline in value, we may be forced to liquidate the investments and realize losses on these investments.

While we intend to hold our investments, which had a fair market value of $4.4 million at March 31, 2020, for the long-term, uncertainties related to the COVID-19 pandemic may require us to liquidate our investments suddenly and, if the markets remain highly volatile, or we have unexpected cash requirements, we may incur losses on future sales of these marketable securities.

24

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Repurchases by us of our common stock during the quarter ended March 31, 2020 were as follows:

Period	Total Number of Shares Purchased		Average Price Paid per Share		Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs		Maximum Number of Shares that May Yet Be Purchased Under the Plans or Programs
January 1, 2020 to January 31, 2020		11,142	$	17.39		11,142		988,858
February 1, 2019 to February 29, 2020		200	$	16.10		200		988,658
March 1, 2020 to March 31, 2020		36,894	$	15.30		36,894		951,764

All repurchases were made pursuant to our previously announced repurchase programs.

ITEM 5. OTHER INFORMATION

As discussed in Note 13 of our condensed financial statements included elsewhere in this report, we received $1,360,100 in proceeds from a PPP Loan on April 10, 2020, which amount we repaid on May 5, 2020 after careful consideration of additional guidance issued by the Small Business Administration and the Department of Treasury.

ITEM 6. EXHIBITS

Exhibit	Description
10.1	Promissory Note, dated April 7, 2020, by and Between Minnesota Bank & Trust and Pro-Dex, Inc. (incorporated herein by reference to Exhibit 10.1 to the Company’s 8-K filed April 14, 2020)
31.1	Certification of Principal Executive Officer Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as amended, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2	Certification of Principal Financial Officer Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as amended, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32	Certifications of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS	XBRL Instance Document
101.SCH	XBRL Taxonomy Extension Schema Document
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF	XBRL Taxonomy Extension Definition
101.LAB	XBRL Taxonomy Extension Label Linkbase Document
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document

25

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

	PRO-DEX, INC.
Date: May 7, 2020	By:	/s/ Richard L. Van Kirk
		Richard L. Van Kirk
		Chief Executive Officer (principal executive officer)

Date: May 7, 2020	By:	/s/ Alisha K. Charlton
		Alisha K. Charlton
		Chief Financial Officer (principal financial officer and principal accounting officer)

26

EXHIBIT INDEX

Exhibit	Description
10.1	Promissory Note, dated April 7, 2020, by and Between Minnesota Bank & Trust and Pro-Dex, Inc. (incorporated herein by reference to Exhibit 10.1 to the Company’s 8-K filed April 14, 2020)
31.1	Certification of Principal Executive Officer Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as amended, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2	Certification of Principal Financial Officer Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as amended, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32	Certifications of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS	XBRL Instance Document
101.SCH	XBRL Taxonomy Extension Schema Document
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF	XBRL Taxonomy Extension Definition
101.LAB	XBRL Taxonomy Extension Label Linkbase Document
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document

27